4D Molecular Therapeutics, Inc. (FDMT) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, filed on August 13, 2026, reports the financial results for 4D Molecular Therapeutics, Inc. for the three months ended June 30, 2026 (Second Quarter 2026). The filing serves to disseminate a press release titled "4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones."
Key Financial Metrics
The provided filing text is a cover page and index for the Form 8-K. It references the press release containing the financial data but does not include the specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for these metrics.
Material Changes
The filing text does not contain specific data regarding material changes versus the prior comparable period. Such details are contained within the referenced Exhibit 99.1 (Press Release), which is not included in the input text.
Guidance, Outlook, and Risks
The filing indicates that the company announced "Operational Highlights and Expected Upcoming Milestones" in the associated press release. However, the specific guidance, management commentary, risks, contingencies, or unusual items are not detailed in the provided text.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) to obtain specific Q2 2026 revenue, net loss, and cash position figures.
- Verify the "Expected Upcoming Milestones" mentioned in the title to understand the company's near-term operational roadmap.
- Compare the Q2 2026 results against Q2 2025 figures once the full press release is accessed to assess year-over-year trends.
- Confirm the company's cash runway and burn rate based on the detailed financial statements referenced in the press release.